Rehmann Capital Advisory Group’s Takeda Pharmaceutical TAK Stock Holding History

Rehmann Capital Advisory Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$322K	Sell	18,709 -111	-0.6%	-$1.92K	0.04%	241
2019 Q2	$333K	Buy	18,820 +4,367	+30%	+$79.5K	0.04%	325
2019 Q1	$294K	Buy	14,453 +14,287	+8,607%	+$287K	0.04%	331
2018 Q4	$2.79K	Buy	+166	New	+$2.8K	﹤0.01%	1377

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Rehmann Capital Advisory Group's TAK Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Takeda Pharmaceutical (TAK) stake by 0.59% in Q3 2019, selling an estimated $1.92K and leaving 18,709 shares worth $322K. The position accounts for 0.04% of the portfolio, ranked #241.

Rehmann Capital Advisory Group first reported a position in TAK in Q4 2018 and has held it in 4 quarters since. The position peaked at $333K in Q2 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

Rehmann Capital Advisory Group held 18,709 shares of Takeda Pharmaceutical worth $322K as of Q3 2019.
Rehmann Capital Advisory Group sold 111 Takeda Pharmaceutical shares in Q3 2019, an estimated $1.92K.
Takeda Pharmaceutical made up 0.04% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #241 holding.
Rehmann Capital Advisory Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 4 quarters since.
Rehmann Capital Advisory Group's Takeda Pharmaceutical position peaked at $333K in Q2 2019.
317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.